KIYATEC Announces Investment from Seae Ventures and Names Co-founder and Managing Partner Jason Robart to its Board of Directors
01 May, 2021
– PharmCADD announced that it has finished USD 16m series B funding on March 31, 2021.
– This funding round was led by Strategic Investors: Huons, Samyang Holdings and SD BIOSENSOR; and Financial Investors: KTB Network, Daily Partners, DSC Investment, KDB Capital, Maple Investment and KB Securities.
– As a result, PharmCADD has secured total of USD 22m in funding since its establishment.
– PharmCADD plans to use the funding not only to launch the U.S. and India-based branches but also to advance its AI & Physics-based drug discovery platform technology, Pharmulator™, and to expand R&D manpower. The funding will be used for the preclinical study of internal pipelines as well.